Hepatitis B
Drug research and approvals for hepatitis B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 146 studies of hepatitis B are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, FDA has 2 approved and 9 open orphan designations naming it, and the EU has 17 authorised medicines for it.
- Recruiting worldwide: 146
- Trials authorized in Canada: 47
- FDA orphan approvals: 2
- EU medicines: 17
- A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal…NCT07944482 · Phase 1 · Fujian Akeylink Biotechnology Co., Ltd. · starts Jul 3, 2026
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant…NCT07855172 · Phase 1 / Phase 2 · Serum Institute of India Pvt. Ltd. · starts Nov 1, 2026
- Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)NCT07855029 · Not reported · Zhiliang Gao · starts Jul 1, 2026
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)NCT07852091 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)NCT07845058 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of LiverNCT07816094 · Phase 4 · Bangladesh Medical University · starts Jan 1, 2026
- Study of BK1803 in Healthy InfantsNCT07793513 · Phase 3 · Tanabe Pharma Corporation · starts Oct 21, 2026
- A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis BNCT07771140 · Phase 1 · Sunshine Lake Pharma Co., Ltd. · starts Dec 2, 2025
- Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCNCT07769827 · Not applicable · Jinling Hospital, China · starts Dec 26, 2025
Approved 8
- EntecavirDNA polymerase/reverse transcriptase inhibitor
- LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- Hepatitis b virus hbsag surface protein antigenSurface antigen (HBsAg) vaccine antigen
- Hepatitis b immune globulinSurface antigen (HBsAg) binding agent
- Hepatitis b virus s protein, PRE-S1 protein and PRE-S2 protein virus like particlesLarge envelope protein vaccine antigen
Phase 1 or earlier 5
- SelgantolimodToll-like receptor 8 agonist
- Bepirovirsen sodium
- BersacapavirCore antigen modulator
- Tobevibart
- Imdusiran sodium
How its trials ended
1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 397 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.
- Completed, result not reported64639%
- Status unknown38923%
- Ongoing24214%
- Met its primary endpoint23514%
- Stopped: other or unclear754%
- Stopped: sponsor or business decision292%
- Missed its primary endpoint221%
- Stopped: enrollment or feasibility221%
- Stopped: lack of efficacy7<1%
- Stopped: safety7<1%
| Oct 2, 2026 | A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standard…AZD6750 | AstraZeneca Pharmaceuticals | Pending |
| Jul 22, 2026 | A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of AHB-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137 | Ausperbio Therapeutics Inc. | Pending |
| May 14, 2025 | A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of ALG-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / Tenofovir disoproxil | Aligos Therapeutics | Ongoing |
| Nov 6, 2024 | A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101 | Arbutus Biopharma | Closed |
| Sep 23, 2024 | A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / Daplusiran-tomligisiran (GSK5637608/JNJ-73763989) | GSK | Ongoing |
| Jul 2, 2024 | A multicenter, randomized, double-blind, placebo- controlled study to assess the efficacy and safety of treatment with bepirovirsen in participants living with…Bepirovirsen (GSK3228836) | GSK | Ongoing |
| Mar 28, 2024 | Four-part, randomized, double-blind (parts 1, 2a, 3 and 4), multi-center, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and…Bepirovirsen (GSK3228836) / GSK3965193 | GSK | Closed |
| Aug 11, 2023 | Phase II investigator-initiated study to understand the vaccinal effect of hbsag monoclonal ab VIR-3434 in chronic hepatitis B infectionVIR-3434 | University Health Network | Ongoing |
| Dec 16, 2022 | A phase 2 study to evaluate the safety, tolerability, and efficacy of regimens containing VIR-2218, VIR-3434, and/or peg-ifn in subjects with chronic hepatitis…Elebsiran (VIR-2218)/ Tobevibart (VIR-3434)/ Peginterferon ALFA-2A | Vir Biotechnology | Ongoing |
| Nov 9, 2022 | Phase 3 multicenter, randomized, double-blind, study to assess the efficacy and safety of treatment with bepirovirsen in nucleos(t)ide analogue treated…Bepirovirsen (GSK3228836) | GSK | Closed |
| Jan 25, 2024 | KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a… | MSD International Business GmbH | Approved |
| Apr 6, 2007 | HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients | Cangene Corporation | Approved |
| Feb 20, 2018 | Tenofovir exalidexTreatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age) | ContraVir Pharmaceuticals, Inc. | Designated |
| May 6, 2013 | Hepatitis B virus neutralizing human monoclonal antibodyPrevention of hepatitis B recurrence following liver transplantation | Green Cross Corp. | Designated |
| Jul 15, 2003 | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation | Cubist Pharmaceuticals | Designated |
| Mar 8, 1995 | Hepatitis B immune globulin intravenous (human)Prophylaxis against hepatitis B virus reinfection in liver transplant patients. | Biotest Pharmaceuticals Corporation | Designated |
| Mar 16, 1994 | Immunotherapeutic vaccine consisting of…Treatment of chronic active hepatitis B infection in HLA-A2 positive patients. | Cytel Corporation | Designated |
| Jul 24, 1992 | FialuridineAdjunctive treatment of chronic active hepatitis B. | Oclassen Pharmaceuticals, Inc. | Designated |
| Jun 17, 1991 | Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection. | Protein Design Labs, Inc. | Designated |
| May 3, 1991 | ThymalfasinTreatment of chronic active hepatitis B | SciClone Pharmaceuticals, Inc. | Designated |
| Nov 17, 1988 | Interferon alfa-2b (recombinant)Treatment of acute hepatitis B. | Schering Corporation | Designated |
| Feb 18, 2021 | Heplisav BHepatitis B surface antigen | Dynavax GmbH | EMA ↗ |
| Sep 25, 2017 | Entecavir AccordEntecavir · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 18, 2017 | Entecavir Viatris (previously Entecavir Mylan)Entecavir · generic | Viatris Limited | EMA ↗ |
| Jan 9, 2017 | VemlidyTenofovir alafenamide | Gilead Sciences Ireland UC | EMA ↗ |
| Feb 15, 2016 | VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) | MCM Vaccine B.V. | EMA ↗ |
| Apr 17, 2013 | HexacimaDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | EMA ↗ |
| Apr 17, 2013 | HexyonDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | EMA ↗ |
| Nov 30, 2009 | ZutectraHuman hepatitis B immunoglobulin | Biotest Pharma GmbH | EMA ↗ |
| Oct 23, 2009 | Lamivudine TevaLamivudine · generic | Teva B.V. | EMA ↗ |
| Jun 26, 2006 | BaracludeEntecavir | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Feb 2, 2005 | FendrixHepatitis B (rDNA) vaccine (adjuvanted, adsorbed) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
| Aug 30, 2002 | AmbirixHepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
| Feb 4, 2002 | VireadTenofovir disoproxil | Gilead Sciences Ireland UC | EMA ↗ |
| Apr 27, 2001 | HBVaxProHepatitis B vaccine (recombinant DNA) | Merck Sharp & Dohme B.V. | EMA ↗ |
| Oct 23, 2000 | Infanrix HexaDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA